Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study [0.03%]
亚洲表皮生长因子受体突变阳性局部晚期或转移性非小细胞肺癌患者一线使用达可替尼治疗的现实世界应用和临床结局：ARIA研究最终分析结果
Lin Wu,Junling Li,Chong-Rui Xu et al.
Lin Wu et al.
Background: Dacomitinib, a second-generation, irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), showed statistically significant progression-free survival improvement over gefitinib in pat...
Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis [0.03%]
PD-1/PD-L1抑制剂联合以铂类为基础的化疗与单纯化疗对比治疗局部晚期或转移性肺淋巴上皮瘤样癌的长期生存分析：更新随访分析
Yanna Tang,Wei Du,Xuanye Zhang et al.
Yanna Tang et al.
Purpose: Pulmonary lymphoepithelioma-like carcinoma (PLELC), a rare Epstein-Barr virus (EBV)-associated non-small-cell lung cancer (NSCLC) subtype, exhibits distinct clinicopathological features but lacks evidence-based f...
Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre [0.03%]
英国三级医疗中心间质性肺病和间质性肺异常患者的放疗结果：不良事件及生存率
Sarah Bowen Jones,Conal Hayton,Ahmed Lodhi et al.
Sarah Bowen Jones et al.
Background: Interstitial lung disease (ILD) encompasses a spectrum of inflammatory and fibrotic lung conditions. Interstitial lung abnormalities (ILA) are incidental radiological findings with the potential to progress to...
Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysis [0.03%]
恩曲替尼治疗ROS1重排阳性非小细胞肺癌亚洲患者：疗效和安全性更新分析
Shun Lu,Yun Fan,Xiaorong Dong et al.
Shun Lu et al.
Background: In an integrated analysis of phase I/II trials (STARTRK-2, STARTRK-1, ALKA-372-001), entrectinib induced responses in global populations with advanced ROS1-fusion positive (ROS1-fp) non-small cell lung cancer ...
KRASG12D/G13D-USP15 axis promotes TGF-β/SMAD signaling and glycolytic flux to accelerate NSCLC pathogenesis [0.03%]
KRASG12D/G13D-USP15轴通过促进TGF-β/SMAD信号传导和糖酵解流量来加速非小细胞肺癌的发生发展
Ikhlas A Sindi,Abdelghafar M Abu-Elsaoud,Amany I Almars et al.
Ikhlas A Sindi et al.
Background: Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related mortality worldwide, with activating KRAS mutations representing a key oncogenic driver. These mutations profoundly reprogram c...
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States [0.03%]
美国ALK阳性晚期非小细胞肺癌酪氨酸激酶抑制剂治疗的患者和肿瘤医生偏好：一种离散选择实验
Hannah Le,Josh Coulter,Ken Culver et al.
Hannah Le et al.
Purpose: Next-generation anaplastic lymphoma kinase (ALK)-targeting tyrosine kinase inhibitors (TKIs) are standard first-line (1L) treatments for ALK+ advanced non-small cell lung cancer (aNSCLC). Treatments differ in sys...
Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma [0.03%]
循环microRNA作为评估风险和预后分层的胸膜间皮瘤生物标志物
Evgeniya Sharova,Paola Del Bianco,Loredana Urso et al.
Evgeniya Sharova et al.
Introduction: Pleural mesothelioma (PM) is an aggressive neoplasm associated with asbestos exposure. Clinical management of PM poses major challenges due to the lack of reliable markers for early diagnosis and prognostic ...
AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer [0.03%]
AXL表达预测非小细胞肺癌转移免疫疗法抵抗性
Julien Ancel,Maxime Dewolf,Béatrice Nawrocki-Raby et al.
Julien Ancel et al.
Background: Non-small cell lung cancer (NSCLC) remains a major therapeutic challenge. While PD-1/PD-L1 immunotherapies have improved outcomes, predictive biomarkers are limited. AXL, a receptor tyrosine kinase associated ...
CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies [0.03%]
针对肺癌CART细胞治疗的现状及展望
Dongxue Shi,Xin Yan,Jianwei Liu et al.
Dongxue Shi et al.
Lung carcinoma has consistently ranked as the most prevalent malignancy and foremost contributor to cancer-related mortality in global epidemiology. Despite the paradigm-shifting advancements in molecularly targeted therapies and immune che...
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE) [0.03%]
加拿大小细胞肺癌数据库（CASCADE）中局限期小细胞肺癌的治疗及预后情况分析
William J Phillips,Luna Jia Zhan,Deepro Chowdhury et al.
William J Phillips et al.
Introduction: There have been minimal advances in the systemic treatment of limited stage small cell lung cancer (LS-SCLC) for decades. With the publication of the ADRIATIC trial, consolidation durvalumab is a new standar...